Ubs Asset Management Americas Inc Revance Therapeutics, Inc. Transaction History

Ubs Asset Management Americas Inc

$381 Billion
Q3 2024

A detailed history of Ubs Asset Management Americas Inc transactions in Revance Therapeutics, Inc. stock. As of the latest transaction made, Ubs Asset Management Americas Inc holds 265,210 shares of RVNC stock, worth $681,589. This represents 0.0% of its overall portfolio holdings.

Number of Shares

265,210

Previous 237,790 11.53%

Holding current value

$681,589

Previous $611,000 11.46%

% of portfolio

0.0%

Previous 0.0%

19 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	BUY	$2.57 - $2.57 $70,469 - $70,469	27,420 Added 11.53%	265,210 $681,000
Q2 2024 Aug 13, 2024	BUY	$2.34 - $4.73 $277,123 - $560,169	118,429 Added 99.22%	237,790 $611,000
Q4 2023 Feb 14, 2024	BUY	$5.81 - $11.2 $50,465 - $97,283	8,686 Added 7.85%	119,361 $1.05 Million
Q3 2023 Nov 13, 2023	BUY	$11.47 - $25.07 $226,658 - $495,408	19,761 Added 21.74%	110,675 $1.27 Million
Q1 2023 May 15, 2023	BUY	$18.36 - $35.27 $218,998 - $420,700	11,928 Added 15.1%	90,914 $2.93 Million
Q4 2022 Feb 14, 2023	BUY	$18.32 - $30.66 $168,012 - $281,182	9,171 Added 13.14%	78,986 $1.46 Million
Q3 2022 Nov 14, 2022	BUY	$14.33 - $28.47 $14,086 - $27,986	983 Added 1.43%	69,815 $1.89 Million
Q2 2022 Aug 12, 2022	BUY	$11.52 - $20.4 $34,571 - $61,220	3,001 Added 4.56%	68,832 $951,000
Q4 2021 Feb 14, 2022	SELL	$12.46 - $27.87 $3.7 Million - $8.27 Million	-296,717 Reduced 81.84%	65,831 $1.07 Million
Q3 2021 Nov 15, 2021	SELL	$25.78 - $33.21 $199,691 - $257,244	-7,746 Reduced 2.09%	362,548 $10.1 Million
Q2 2021 Aug 16, 2021	SELL	$26.8 - $31.84 $371,501 - $441,366	-13,862 Reduced 3.61%	370,294 $11 Million
Q1 2021 May 14, 2021	BUY	$24.03 - $29.97 $227,804 - $284,115	9,480 Added 2.53%	384,156 $10.7 Million
Q4 2020 Mar 01, 2021	BUY	$23.41 - $28.34 $7.78 Million - $9.42 Million	332,453 Added 787.37%	374,676 $10.6 Million
Q3 2020 Nov 13, 2020	BUY	$23.23 - $34.3 $29,920 - $44,178	1,288 Added 3.15%	42,223 $1.06 Million
Q2 2020 Aug 14, 2020	BUY	$12.6 - $26.55 $73,974 - $155,875	5,871 Added 16.74%	40,935 $999,000
Q1 2020 May 15, 2020	BUY	$12.46 - $27.81 $61,041 - $136,241	4,899 Added 16.24%	35,064 $518,000
Q4 2019 Feb 14, 2020	BUY	$11.66 - $20.15 $187,469 - $323,971	16,078 Added 114.13%	30,165 $489,000
Q3 2019 Nov 14, 2019	BUY	$10.22 - $14.5 $10,782 - $15,297	1,055 Added 8.1%	14,087 $183,000
Q1 2019 May 14, 2019	BUY	$15.4 - $20.39 $200,692 - $265,722	13,032 New	13,032 $0

Others Institutions Holding RVNC

# of Institutions

234

Shares Held

82.8M

Call Options Held

680K

Put Options Held

896K

View Full List

About Revance Therapeutics, Inc.

Ticker RVNC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 82,305,696
Market Cap $212M
Description
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DaxibotulinumtoxinA for injection, which has completed phase III clinical trials fo...

More about RVNC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Ubs Asset Management Americas Inc, based on Form 13F filings with the SEC.

News

Stay updated on Ubs Asset Management Americas Inc with notifications on news.

Account

Ubs Asset Management Americas Inc Revance Therapeutics, Inc. Transaction History